These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. D'Arcy P; Brnjic S; Olofsson MH; Fryknäs M; Lindsten K; De Cesare M; Perego P; Sadeghi B; Hassan M; Larsson R; Linder S Nat Med; 2011 Nov; 17(12):1636-40. PubMed ID: 22057347 [TBL] [Abstract][Full Text] [Related]
3. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Coughlin K; Anchoori R; Iizuka Y; Meints J; MacNeill L; Vogel RI; Orlowski RZ; Lee MK; Roden RB; Bazzaro M Clin Cancer Res; 2014 Jun; 20(12):3174-86. PubMed ID: 24727327 [TBL] [Abstract][Full Text] [Related]
4. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Bazzaro M; Lee MK; Zoso A; Stirling WL; Santillan A; Shih IeM; Roden RB Cancer Res; 2006 Apr; 66(7):3754-63. PubMed ID: 16585202 [TBL] [Abstract][Full Text] [Related]
5. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Kapuria V; Peterson LF; Fang D; Bornmann WG; Talpaz M; Donato NJ Cancer Res; 2010 Nov; 70(22):9265-76. PubMed ID: 21045142 [TBL] [Abstract][Full Text] [Related]
6. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Tian Z; D'Arcy P; Wang X; Ray A; Tai YT; Hu Y; Carrasco RD; Richardson P; Linder S; Chauhan D; Anderson KC Blood; 2014 Jan; 123(5):706-16. PubMed ID: 24319254 [TBL] [Abstract][Full Text] [Related]
7. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line. Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590 [TBL] [Abstract][Full Text] [Related]
8. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Achanta G; Modzelewska A; Feng L; Khan SR; Huang P Mol Pharmacol; 2006 Jul; 70(1):426-33. PubMed ID: 16636137 [TBL] [Abstract][Full Text] [Related]
9. Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells. Anchoori RK; Khan SR; Sueblinvong T; Felthauser A; Iizuka Y; Gavioli R; Destro F; Isaksson Vogel R; Peng S; Roden RB; Bazzaro M PLoS One; 2011; 6(8):e23888. PubMed ID: 21909374 [TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Berges C; Haberstock H; Fuchs D; Miltz M; Sadeghi M; Opelz G; Daniel V; Naujokat C Immunology; 2008 Jun; 124(2):234-46. PubMed ID: 18217957 [TBL] [Abstract][Full Text] [Related]
11. Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype. Issaenko OA; Bitterman PB; Polunovsky VA; Dahlberg PS Cancer Gene Ther; 2012 Sep; 19(9):609-18. PubMed ID: 22767218 [TBL] [Abstract][Full Text] [Related]
12. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Pei XY; Dai Y; Grant S Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093 [TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476 [TBL] [Abstract][Full Text] [Related]
14. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Yerlikaya A; Erin N Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781 [TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676 [TBL] [Abstract][Full Text] [Related]
16. MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity. Gopalan B; Shanker M; Scott A; Branch CD; Chada S; Ramesh R Cancer Gene Ther; 2008 Jan; 15(1):1-8. PubMed ID: 17828282 [TBL] [Abstract][Full Text] [Related]
17. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. Ling YH; Liebes L; Zou Y; Perez-Soler R J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Ling YH; Liebes L; Jiang JD; Holland JF; Elliott PJ; Adams J; Muggia FM; Perez-Soler R Clin Cancer Res; 2003 Mar; 9(3):1145-54. PubMed ID: 12631620 [TBL] [Abstract][Full Text] [Related]
19. Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress. Brnjic S; Mazurkiewicz M; Fryknäs M; Sun C; Zhang X; Larsson R; D'Arcy P; Linder S Antioxid Redox Signal; 2014 Dec; 21(17):2271-85. PubMed ID: 24011031 [TBL] [Abstract][Full Text] [Related]
20. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Combaret V; Boyault S; Iacono I; Brejon S; Rousseau R; Puisieux A Mol Cancer; 2008 Jun; 7():50. PubMed ID: 18534018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]